Ligand Pharmaceuticals will report Q4 and full-year 2025 results on February 26, 2026, with a conference call at 8:30 AM ET.
Quiver AI Summary
Ligand Pharmaceuticals Incorporated announced it will release its financial results for the fourth quarter and full year of 2025 on February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss the results and provide a business update. The call can be accessed via phone or webcast, and details, including conference call numbers and IDs, were provided. Ligand is a biopharmaceutical company focused on supporting the development of high-value medicines through financing and licensing technologies, while partnering with leading pharmaceutical companies to generate revenue. The company operates with two main technologies, Captisol® and NITRICIL™, aimed at improving drug solubility and stability, and enabling tunable dosing. For more information, Ligand encourages investors to visit their website and follow their updates on social media.
Potential Positives
- Ligand Pharmaceuticals will report its fourth quarter and full year 2025 financial results, providing transparency and updates to stakeholders.
- The scheduled conference call aims to offer insights into the business's performance and future direction, engaging with investors and analysts.
- Ligand's business model focuses on generating value for stockholders through strategic partnerships and a diversified revenue portfolio, enhancing investor confidence.
- The mention of established alliances with leading pharmaceutical companies underscores Ligand’s credibility and collaborative strength in the biopharmaceutical industry.
Potential Negatives
- None
FAQ
When will Ligand Pharmaceuticals report its financial results?
Ligand Pharmaceuticals will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026.
What time is the conference call for investors?
The conference call will begin at 8:30 a.m. Eastern Time on February 26, 2026.
How can I access the conference call and webcast?
You can access the conference call by dialing (800) 715-9871 for U.S. and Canada, or (646) 307-1963 internationally.
What is the focus of Ligand Pharmaceuticals' business model?
Ligand focuses on supporting clinical development of medicines by providing financing, licensing technologies, and generating diversified revenue streams.
Who are Ligand Pharmaceuticals' notable partnerships with?
Ligand has established partnerships with leading companies like Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LGND Insider Trading Activity
$LGND insiders have traded $LGND stock on the open market 36 times in the past 6 months. Of those trades, 0 have been purchases and 36 have been sales.
Here’s a breakdown of recent trading of $LGND stock by insiders over the last 6 months:
- JASON ARYEH has made 0 purchases and 3 sales selling 10,000 shares for an estimated $1,708,087.
- NANCY RYAN GRAY has made 0 purchases and 2 sales selling 6,571 shares for an estimated $1,350,011.
- JOHN L LAMATTINA has made 0 purchases and 2 sales selling 4,179 shares for an estimated $858,575.
- JOHN W KOZARICH has made 0 purchases and 28 sales selling 2,802 shares for an estimated $520,273.
- OCTAVIO ESPINOZA (Chief Financial Officer) sold 1,804 shares for an estimated $339,711
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LGND Revenue
$LGND had revenues of $162M in Q3 2025. This is an increase of 94.02% from the same period in the prior year.
You can track LGND financials on Quiver Quantitative's LGND stock page.
$LGND Hedge Fund Activity
We have seen 177 institutional investors add shares of $LGND stock to their portfolio, and 137 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 431,008 shares (+1643.6%) to their portfolio in Q3 2025, for an estimated $76,348,757
- ACUITAS INVESTMENTS, LLC removed 402,494 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $76,099,540
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 361,413 shares (+92.2%) to their portfolio in Q3 2025, for an estimated $64,020,698
- FRANKLIN RESOURCES INC added 266,304 shares (+115.9%) to their portfolio in Q4 2025, for an estimated $50,350,097
- VICTORY CAPITAL MANAGEMENT INC added 221,996 shares (+676.6%) to their portfolio in Q3 2025, for an estimated $39,324,371
- CONGRESS ASSET MANAGEMENT CO removed 187,248 shares (-28.1%) from their portfolio in Q4 2025, for an estimated $35,402,979
- DIMENSIONAL FUND ADVISORS LP removed 180,609 shares (-25.6%) from their portfolio in Q3 2025, for an estimated $31,993,078
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LGND Analyst Ratings
Wall Street analysts have issued reports on $LGND in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 12/10/2025
- Citigroup issued a "Buy" rating on 12/09/2025
- Benchmark issued a "Buy" rating on 11/07/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/06/2025
- Oppenheimer issued a "Outperform" rating on 09/03/2025
To track analyst ratings and price targets for $LGND, check out Quiver Quantitative's $LGND forecast page.
$LGND Price Targets
Multiple analysts have issued price targets for $LGND recently. We have seen 6 analysts offer price targets for $LGND in the last 6 months, with a median target of $233.0.
Here are some recent targets:
- Annabel Samimy from Stifel set a target price of $230.0 on 12/10/2025
- Douglas Miehm from RBC Capital set a target price of $235.0 on 12/10/2025
- Yigal Nochomovitz from Citigroup set a target price of $270.0 on 12/09/2025
- Robert Wasserman from Benchmark set a target price of $220.0 on 11/07/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $231.0 on 11/06/2025
- Trevor Allred from Oppenheimer set a target price of $250.0 on 11/03/2025
Full Release
JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will hold a conference call beginning at 8:30 a.m. ET to discuss the results and provide a general business update.
|
Conference Call and Webcast Information
|
|
| Date: | Thursday, February 26, 2026 |
| Time: | 8:30 AM Eastern Time |
| Conference Call: |
(800) 715-9871 (U.S. & Canada)
(646) 307-1963 (International) Conference ID 3661098 |
| Webcast: | Live and replay webcasts of the call are available here . |
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit
www.ligand.com
. Follow Ligand on
X
and
LinkedIn
.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
Contacts
Investors:
Melanie Herman
[email protected]
(858) 550-7761
Media:
Kellie Walsh
[email protected]
(914) 315-6072
